Skip to content

Diagnosing Variable Primary Aldosteronism.

Do we Miss a Common Subset of Primary Aldosteronism in Which There is Cyclical or Exaggerated Diurnal Variation in Secretion?

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05765786
Enrollment
100
Registered
2023-03-13
Start date
2023-02-24
Completion date
2027-07-24
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Pressure, Primary Aldosteronism

Brief summary

The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.

Detailed description

The main questions it aims to answer are: * Can we diagnose more people if we used 24 hour urine measurements? * In those with high amounts of aldosterone in their urine, is there a variable pattern to their aldosterone production? Participants will have a 24 hour urine measurement. They will also have multiple blood tests throughout the day to study the variability in aldosterone secretion.

Interventions

None listed

Sponsors

Queen Mary University of London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \<0.5 nmol/h/L or renin mass \<5 ng/L), plasma sodium \> 140mmol/L or plasma potassium \< 4mmol/L. * Patients who have been diagnosed with PA and had previous aldosterone samples \<277 pmol/L, a level which would normally not qualify for confirmatory testing. * Patients with aldosterone results done at different times that indicate variability in production. * Willing to consent and participate in the study.

Exclusion criteria

* Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks. * People on end of life treatment.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of 24 hour urine tetrahydroaldosterone excretion.12 monthsCan measurement of 24 hour urine tetrahydroaldosterone excretion detect more people with PA than current conventional screening tests?

Secondary

MeasureTime frameDescription
Differences in timed day and night urine THA measurements.12 monthsWe will be measuring the 24 hour urine THA samples in two separate (approximately 12 hours each) collections, one in the day and one at night. We can then study if there are any differences between day time and night time secretion which may help us understand the diurnal variation in aldosterone secretion.
Variation in aldosterone secretion from day series in those with positive 24h urine THA and those with negative 24h urine THA.12 monthsThis will allow us to study further if the reason why their screening blood test did not meet the threshold for diagnosis.
Complete or partial clinical cure rate of this cohort of patients that qualify for adrenalectomy12 monthsComplete clinical cure is daytime home or ambulatory BP \< 135/\<85mmHg, on no treatment. Partial clinical cure is BP \< 135/\<85 mmHg on the same or fewer drugs, not including a K+-sparing diuretic.
Complete biochemical cure of PA in this cohort of patients that qualify for adrenalectomy.12 monthsThis is defined as (whilst off medications that might alter serum potassium or the RAS) by both: 1. normalization of serum potassium and normalization of ARR or 2. elevated ARR and either baseline PAC \<190pmol/L, or normal confirmatory test (saline infusion test or captopril challenge test).

Countries

United Kingdom

Contacts

CONTACTYun Ni Lee
y.n.lee@qmul.ac.uk+442078827275
CONTACTTumi Kaminskas
research.governance@qmul.ac.uk+442078827275
PRINCIPAL_INVESTIGATORWilliam Drake, Prof

Queen Mary University of London

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026